Corporate Profile

Exicure, Inc. is a clinical stage biotechnology company developing a new class of immunomodulatory and gene regulating drugs against validated targets. Exicure's proprietary 3-dimensional, spherical nucleic acid (SNA™) architecture unlocks the potential of therapeutic oligonucleotides in a wide range of cells and tissues. Exicure'Read More

Stock Information

XCUR (Common Stock) $3.70 Stock is Up 0.09 (2.49%)Data as of 11/16/18 4:00 p.m. ET
Data provided by Nasdaq. Minimum 15 minutes delayed.

Stock Chart

Stock chart for: XCUR.PK.  Currently trading at $3.70 with a 52 week high of $6.50 and a 52 week low of $3.02.

Press Releases

Upcoming Events

Print Page  | E-mail Page  | RSS Feeds  | E-mail Alerts  | IR Contacts  | Financial Tear Sheet